The transcription factor NF-κB plays critical roles in diverse physiological processes (
Ghosh and Karin, 2002) and numerous human pathologies (
Karin et al., 2004). The primary mediator of NF-κB transcriptional activity is a RelA:p50 heterodimer. Mouse knockout studies have confirmed that RelA is responsible for the expression of a large number of genes involved in inflammatory responses as well as in cell proliferation, cell adhesion and tissue remodeling (
Hoffmann and Baltimore, 2006). NF-κB activity is inducible by a diverse range of stimuli (
www.nf-kb.org); these include pathogen derived substances and inter-cellular mediators of inflammation, immune cell maturation and secondary lymphoid organ development. Understanding the mechanisms that regulate NF-κB activity is critical for developing therapeutic strategies for many human diseases (
Ghosh and Karin, 2002;
Hoffmann and Baltimore, 2006;
Karin et al., 2004).
Induction of NF-κB/RelA activity in response to inflammatory stimuli does not require protein synthesis. Instead, early experiments distinguished between two activation mechanisms: a precursor processing mechanism, or regulation by a separate inhibitor protein. The detergent deoxycholate was shown to liberate fully active κB-site DNA binding activity in unstimulated cells, suggesting the existence of a separate inhibitor protein(s), termed IκB (
Baeuerle and Baltimore, 1988). Three IκB proteins (IκBα, -β, or -ε) have been identified, which share the
bona fide IκB properties of (1) binding NF-κB dimers thereby inhibiting their DNA binding activity and retaining them in a latent state and (2) allowing for NF-κB activation by undergoing stimulus-induced proteolysis. The “canonical” signaling pathway involves the stimulus-responsive phosphorylation of the IκBs by the NEMO and IKK2 containing kinase complex, which tags them for degradation via the ubiquitin-proteasome pathway. Several other IκB-like ankyrin-repeat containing NF-κB binding proteins have been reported to modulate nuclear NF-κB transcriptional activity on a subset of genes (
Yamamoto et al., 2004) or, when over-expressed, prevent nuclear localization of NF-κB (
Hatada et al., 1992;
Inoue et al., 1992;
Naumann et al., 1993). However, during inflammatory signaling the dynamic control of NF-κB nucleocytoplasmic localization is mediated by the three classical IκB proteins (Hoffmann et al.;
Tergaonkar et al., 2005). A detailed molecular understanding of the biochemical events has allowed for the construction of a mathematical model that recapitulates the experimentally observed signaling behavior in response to inflammatory stimuli (
Hoffmann et al., 2002;
Kearns et al., 2006;
Werner et al., 2005).
In contrast, a second NF-κB activation pathway is thought to regulate the activity of NF-κB/RelB dimers
via a precursor processing mechanism. This signaling pathway is activated in response to developmental signals such as those transduced by lymphotoxin beta receptor (LTβR) and RANK, which are required for lymph node and osteoclast genesis and homeostasis (
Senftleben et al., 2001;
Weih and Caamano, 2003), or BAFFR, CD40 and CD27, which regulate B-cell survival and proliferation (
Ramakrishnan et al., 2004;
Zarnegar et al., 2004). The activation mechanism was shown to involve NF-κB-inducing kinase (NIK) and IKK1-dependent phosphorylation of the
nfkb2 gene product p100 (
Dejardin et al., 2002), which triggers its proteasomal processing. This partial proteolysis event removes a C-terminal ankyrin repeat domain (IκB-like domain), to generate the NF-κB protein p52 (
Senftleben et al., 2001). Interestingly, only newly synthesized p100 was shown to undergo processing to generate nuclear p52-containing nuclear NF-κB activities (
Mordmuller et al., 2003).
The physiological role of LTβR is to transduce signals from hematopoietically derived lymphoid tissue inducer cells expressing membrane bound lymphotoxin (LTαβ) to mesenchymal or stromal cells to initiate critical steps in lymph node development (
Mebius, 2003;
Rennert et al., 1998). LTβR stimulation results in both RelA and RelB-containing NF-κB dimers (
Muller and Siebenlist, 2003). The vascular-cell adhesion molecule 1 (VCAM1), a prominent RelA target gene, mediates early steps in lymph node genesis, the formation of lymph node anlagen during embryogenesis. Subsequently, homing of B-cells, whose interaction with stromal cells is critical for lymph node and splenic microarchitecture, requires lymphoid chemokines SLC/CCL21 and BLC/CXCL13, whose expression is thought to involve RelB (
Bonizzi et al., 2004). The maturation of spleen and lymph nodes and continued influx and organization of lymphocytes in these secondary lymphoid organs during adulthood, is also dependent on LTβR signaling and the expression of the RelA target gene MadCAM (
Browning et al., 2005). The phenotypes of knockout mice reflect the requirement of both RelA- and RelB-containing NF-κB activities. While RelA-deficiency results in a complete absence of lymph nodes in new born mice indicating an early organogenic defect (
Alcamo et al., 2002), RelB appears to be required for their maintenance as RelB-deficient mice exhibit deterioration of nodes following birth (
Weih et al., 2001).
Despite the importance of RelA activity in lymph node genesis, the molecular mechanism responsible for LTβR-induced RelA:p50 dimer activation has remained unclear. Both an IκB-dependent (
Muller and Siebenlist, 2003) and an IκB-independent (
Jiang et al., 2003) activation mechanism has been proposed, and for CD27 signaling the non-canonical signal transducer NIK has been implicated (
Ramakrishnan et al., 2004). Here we report the existence of a fourth
bona fide IκB protein that mediates RelA:p50 activation in response to non-canonical NF-κB signaling pathways. Reconstruction of the signaling mechanism in a mathematical model allowed us to demonstrate that this mechanism is sufficient to account for the experimental observables and explore signaling crosstalk in cells exposed to diverse NF-κB inducing stimuli.